New drug combo aims to tackle tough lymphoma
NCT ID NCT06453044
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of two targeted drugs, mosunetuzumab and polatuzumab vedotin, in about 41 adults with follicular lymphoma that has relapsed or is refractory. The drugs work by helping the immune system attack cancer cells and delivering a toxic agent directly to them. The main goals are to see how safe the combination is and how many patients achieve a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mosunetuzumab and polatuzumab vedotin
What this could lead to
If this works, it could offer a new treatment option for people with follicular lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is an early phase 2 trial with only 41 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Orange County Lennar Foundation Cancer Center
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact